Header
For Healthcare Professionals

India: Differentiation v/s other FDCs

3-2-1 banner

Differentiation v/s other FDCs

Glyxambi_infographic01
Glyxambi_infographic01

References

  1. GLYXAMBI® India pack insert version. 15 May 2024.

  2. Zinman B, Wanner C, Lachin JM, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med. 2015;373(22):2117-2128.

  3. Rosenstock J, Perkovic V, Johansen OE, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA. 2019;321(1):69-79.

  4. Wanner Ch, Inzucchi SE, Zinman B. Empagliflozin and Progression of Kidney Disease in Type 2 Diabetes. N Engl J Med. 2016;375(18):1801-1802.

  5. DeFronzo RA, et al. Diabetes Care. 2015;38(3):384-393. (based on subgroup analysis of patients with HbA1c ≥8.5% at baseline).

  6. Clinical Trials Registry. http://ctri.nic.in/ Clinicaltrials/pdf_generate.php?trialid=55328&EncHid=&modid=&compid=%27,%2755328det%27/accessed August 1, 2022.

  7. Wiviott SD, Raz I, Bonaca MP, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2019;380(4):347-357.

  8. Green JB, Bethel MA, Armstrong PW, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med. 2015;373(3):232-242.

  9. Gluxit-S® India pack insert version: June 2022.

  10. Kovil R, et al. JAPI. 2020. Accessed from: https://www.japi.org/x2649454/single-pill-combination-of-empagliflozin-and-linagliptin-in-real¬world-indian -type-2-diabetes-patient-grid. Accessed on Dec 7, 2020.

  11. Joshi S, Endocr Pract. 2020. Accessed from: https://www.endocrinepractice.org/article/S1530-891X(20)39836-0/pdf. Accessed on Jan 19, 2020.

  12. Bhattacharya S. Abstract #1003971: Efficacy and Safety of Empagliflozin and Linagliptin Combination in Non-hospitalized COVID-19 Positive Patients with T2DM in Real World Setting: A Single Center Retrospective Study. Endocr Pract. 2021;27(6):S57.

  13. Gupta A, Malhotra P, Jamwal V et al. A Retrospective Analysis of Fixed Combination of Empagliflozin and Linagliptin in Addition to the Existing Treatment for its Clinical Effectiveness in Adults with Type 2 Diabetes: A Real-World Clinical Experience. J Assoc Physicians India. 2021;69(7):11-12.

  14. Bhattacharyya S, Khalse M. Clinical Effectiveness of Empagliflozin and Linagliptin Combination in Overweight or Obese T2DM Patients: Indian Real-World Experience. Int J Diab 2020;14-18.

  15. Bhattacharyya S, Mishra AB, Khalse M. Clinical effectiveness of fixed dose combination of empagliflozin and linagliptin (empa/lina) in patients with type 2 diabetes mellitus unwilling to continue basal insulin
    therapy: a real-world experience in Indian setting. Indian J Appl Res. 2021;11(10):42-44.

  16. Bhattacharyya S. Diabetes. 2021;70(Supplement 1).14.

MLR ID: PC-IN-104937
Expiry Date: 7/9/2027